Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer

BACKGROUND: The optimal number of 3-wk docetaxel plus prednisone (DP) cycles for metastatic castration-resistant prostate cancer (mCRPC) is unclear. OBJECTIVE: A retrospective analysis of two clinical trials was performed to evaluate the association of the number of cycles with overall survival (OS)...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Pond, Gregory R., Armstrong, Andrew J., Wood, Brian A., Brookes, Melissa, Leopold, Lance, Berry, William R., de Wit, Ronald, Eisenberger, Mario A., Tannock, Ian F., Sonpavde, Guru
Format: Artigo
Jezik:Inglês
Izdano: 2011
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3483076/
https://ncbi.nlm.nih.gov/pubmed/21715086
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2011.06.034
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki